Is Atripla a feasible switch option in patients with an existing M184V mutation?

被引：0
|
作者：
Rockwood, N. [1 ]
Singh, G. Jagjit [1 ]
Nelson, M. [1 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
来源：
HIV MEDICINE | 2011年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [31] Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation
    Zaccarelli, M
    Perno, CF
    Forbici, F
    Cingolani, A
    Liuzzi, G
    Bertoli, A
    Trotto, MP
    Bellocchi, MC
    Di Giambenedetto, S
    Tozzi, V
    Gori, C
    D'Arrigo, R
    De Longis, P
    Noto, P
    Girardi, E
    De Luca, A
    Antinori, A
    ANTIVIRAL THERAPY, 2003, 8 (01) : 51 - 56
  • [32] Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine
    Murry, JP
    Higgins, J
    Matthews, TB
    Huang, VY
    Van Rompay, KKA
    Pedersen, NC
    North, TW
    JOURNAL OF VIROLOGY, 2003, 77 (02) : 1120 - 1130
  • [33] Impact of the M184V/I on protease inhibitor susceptibilities in protease inhibitor-naive patients
    Shulman, NS
    Bosch, RJ
    Albrecht, M
    Hellmann, N
    Katzenstein, DA
    ANTIVIRAL THERAPY, 2004, 9 (04) : U66 - U66
  • [34] Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis
    Wei, X
    Liang, C
    Götte, M
    Wainberg, MA
    VIROLOGY, 2003, 311 (01) : 202 - 212
  • [35] Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients
    Winters, MA
    Bosch, RJ
    Albrecht, MA
    Katzenstein, DA
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (04): : 537 - 540
  • [36] ENTECAVIR MONOTHERAPY SELECTS M184V MUTATION IN LAMIVUDINE-NAiVE AND LAMIVUDINE EXPERIENCED HIV-HBV CO-INFECTED PATIENTS
    Castel, Helene
    Bocket, Laurence
    Tamalet, Catherine
    Bourliere, Marc
    Yazdanpanah, Yazdan
    HEPATOLOGY, 2008, 48 (04) : 728A - 728A
  • [37] Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation
    Mimtsoudis, Iordanis
    Tsachouridou, Olga
    Akinosoglou, Karolina
    Metallidis, Symeon
    VIRUSES-BASEL, 2024, 16 (09):
  • [38] Differential impact of mutations M184V, M184I and M184T in HIV-1 RT on entecavir incorporation and susceptibility
    Van Maarseveen, N. M.
    Bernatchez, J. A.
    De Jong, D.
    Schinazi, R. F.
    Gotte, M.
    Nijhuis, M.
    ANTIVIRAL THERAPY, 2011, 16 : A65 - A65
  • [39] SUSTAINED VIRAL SUPPRESSION AMONG PARTICIPANTS WITH PRE-EXISTING M184V/I WHO SWITCHED TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE
    Andreatta, K.
    Acosta, R.
    D'Antoni, M. L.
    Porter, D. P.
    Chang, S.
    Martin, R.
    Willkom, M.
    McNicholl, I.
    Gallant, J.
    Pikora, C.
    Collins, S.
    Martin, H.
    Fagan, D.
    White, K. L.
    SEXUAL HEALTH, 2020, 17 (05) : XXIII - XXIII
  • [40] Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV
    Chen, Guan-Jhou
    Lee, Yu-Lin
    Lee, Chen-Hsiang
    Sun, Hsin-Yun
    Cheng, Chien-Yu
    Tsai, Hung-Chin
    Huang, Sung-Hsi
    Lee, Yi-Chieh
    Hsieh, Min-Han
    Chang, Sui-Yuan
    Chuang, Yu-Chung
    Su, Li-Shin
    Chang, Sui-Fang
    Tang, Hung-Jen
    Hung, Chien-Ching
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (10) : 2986 - 2993
12345